Treatment regimen for the treatment of neurological diseases or conditions

A method of treating a neurological disease or condition which results in the destruction or degeneration of neurons, axons or myelin;

• wherein the method comprises:
• administering a compound of formula (I) or a pharmaceutically acceptable salt thereof or pharmaceutical composition thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically acceptable salts:
• wherein the compound of formula (I) is:
• wherein:
• R1 is phenyl substituted with halogen or trifluoromethyl, and further optionally substituted with one or two substituents selected from the group consisting of halogen, (C1-C6) alkyl, (C1-C6) alkoxy, and halo (C1-C6) alkyl;
• or alternatively R1 is pyrrolidin-1-yl;
• R2 is 2-oxo-pyrrolidin-1-ylmethyl or sulfamoylphenyl;
• and
• R3 is selected from the group consisting of propyl, 1-methylethyl, butyl, 2-methylpropyl, pentyl, 1-methylbutyl, 2-methylbutyl, hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, and 1-methylpentyl;
• wherein the method includes a discontinuous treatment regimen comprising:
• a) a first time period 5 to 7 days, wherein the compound is administered once a day to a subject in need thereof, and
• b) a second time period equal to or longer than 13 days, wherein the compound is not administered;
• and
• wherein the second time period takes place after the first time period and before the next administration of the compound;
• wherein the therapeutic effect of the treatment in the first time period extends through the second time period such that there is a neuroprotective effect during both the first time period and the second time period.